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Abstract
This article reports the conclusions of the second part of a consensus expert conference on the nomenclature
of renal replacement therapy (RRT) techniques currently utilized to manage acute kidney injury and other organ
dysfunction syndromes in critically ill patients. A multidisciplinary approach was taken to achieve harmonization
of definitions, components, techniques, and operations of the extracorporeal therapies. The article describes the
RRT techniques in detail with the relevant technology, procedures, and phases of treatment and key aspects of
volume management/fluid balance in critically ill patients. In addition, the article describes recent developments
in other extracorporeal therapies, including therapeutic plasma exchange, multiple organ support therapy, liver
support, lung support, and blood purification in sepsis. This is a consensus report on nomenclature harmonization
in extracorporeal blood purification therapies, such as hemofiltration, plasma exchange, multiple organ support
therapies, and blood purification in sepsis.
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Background
The use of renal replacement therapy (RRT) in the manage-
ment of acute kidney injury (AKI) requires a multidisciplin-
ary approach. It is, therefore, essential that all members of
the team use the same terminology, but the terms used to
describe the different modalities of RRT often vary and can
be confusing. In this article, we provide an updated consen-
sus nomenclature to help navigate this complex field. We
review the practical applications of transmembrane solute
and fluid transport principles and the control mechanisms
for RRT devices. The article focuses on continuous renal
replacement therapies (CRRTs), which are commonly used
in the treatment of critically ill patients. We hope that this
standardized terminology will be adopted by all involved in
this field, including industry as they develop new devices.
Methodology
A conference was organized in Vicenza, Italy, to gather
experts in CRRT and members of companies manufac-
turing CRRT hardware and devices to establish consensus
on technical terminology and definitions relevant to basic
principles of CRRT and related technologies [1]. The
conference provided the background for a modified
Delphi consensus methodology as previously utilized for
the Acute Disease Quality initiative consensus sessions
[2]. Prior to the conference, participants screened the lit-
erature of the last 25 years and previous taxonomy efforts
[3–5]. Keywords included “continuous renal replacement
therapy”, “dialysis”, “hemofiltration”, “convection”, “diffu-
sion”, “ultrafiltration”, “dose”, “blood purification”, “renal
support”, “multiorgan dysfunction”, together with the rela-
tive MeSH (Medical Subject Headings) terms. Abstracts of
707 articles were screened and more than 300 papers were
read in full and analyzed. Based on this literature search, a
series of definitions and terms were proposed and consen-
sus was achieved from the majority of experts who partici-
pated in the conference. Where consensus was lacking,
different statements were created after two-thirds of the
audience expressed a positive vote. We present the results
of this effort of terminology harmonization called the
Nomenclature Standardization Initiative (NSI).
Hardware and devices
CRRT “hardware” includes the machine and all dedicated
disposables. Knowledge of the nomenclature and the func-
tions of the machine and its main components is extremely
important, not only for nurses and technicians but also for
clinicians.
Figure 1 depicts a standard CRRT machine equipped
with current technology and characteristics [6, 7]. Its
main components include:
1. Screen: the monitor through which the user
interacts with the machine.
2. Alarm light and sound indicators: visual and
auditory alarms must be clear and comprehensive.
The alarm settings should be unequivocally
categorized according to a specific standard.
3. In-flow pressure (PIN) sensor (upstream of blood
pump): monitors the negative pressure in the blood
in-flow line between the patient’s vascular access
and the blood pump.
4. Blood pump: pump that controls the blood flow rate
through the extracorporeal circuit.
Fig. 1 The CRRT machine (see the text for explanation of numbered
components)
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5. Pre-blood pump: pump that controls the flow
rate of solutions, mainly regional anticoagulants
(e.g., citrate), into the blood in-flow line before
the blood pump.
6. Pre-blood pump pressure sensor: monitors the
pressure before the pre-blood pump.
7. Pre-filter pressure (PPRE) sensor (downstream of
blood pump): located in the blood flow line
between the blood pump and filter, this sensor
monitors the positive pressure and enables
calculation of the transmembrane pressure (TMP)
and pressure drop (PDROP) in the filter.
8. Filter holder: holds the filter or the entire filter-tubing
kit on the machine.
9. Out-flow pressure (POUT) sensor: monitors the
positive pressure between the filter and the patient
vascular access. This sensor is used to calculate the
TMP and pressure drop in the filter.
10. Bubble detector: a transducer that detects the
presence of air in the blood out-flow line.
11. Safety out-flow electroclamp: a mechanism that
produces occlusion of the blood out-flow line.
12. Effluent/ultrafiltrate pump: pump that controls the
rate of total fluid removal from the filter.
13. Effluent/ultrafiltrate pressure (PEFF) sensor: monitors
the pressure in the effluent compartment of the
filter. This sensor is placed before the effluent
pump and allows calculation of the TMP.
14. Blood leak detector (BLD): placed along the effluent
line, it identifies unwanted blood leaks from the
blood compartment of the filter.
15. Replacement/infusion pump: the pump that controls
the rate of replacement fluid flow into the blood
in-flow line (pre-dilution, usually between the blood
pump and the filter) and/or into the blood out-flow
line (post-dilution, usually in the blood out-flow
chamber, such as the deaeration or venous drip
chamber).
16. Pre-replacement pump pressure sensor: monitors
the negative pressure before the replacement
pump.
17. Dialysate pump: the pump that controls the rate of
dialysate flow into the filter.
18. Pre-dialysate pump pressure sensor: monitors the
negative pressure before the dialysate pump.
19. Post-dialysate pump pressure (PDi) sensor: monitors
the pressure in the dialysate line before the
connection with the filter. Permits a better
estimate of TMP.
20. Fluid control system: allows direct monitoring of the
fluid balance related to fluids exchanged by the
CRRT machine during the treatment. It can be
gravimetric, volumetric, fluximetric, or a
combination of these mechanisms.
21. Heater: heats the dialysate/replacement fluids or the
blood flowing through the blood out-flow line of
the extracorporeal circuit.
22. Anticoagulant pump: infuses anticoagulants into
the blood circuit. Depending on the anticoagulation
modality chosen, this pump can be a single unit
(systemic anticoagulation, e.g., heparin) or be a part
of a more complex infusion system with multiple
pumps. In fact, in cases of regional anticoagulation
(heparin-protamin or citrate-calcium) a second
pump is necessary to infuse the antagonist of the
selected anticoagulant into the blood out-flow line.
CRRT machine: procedures and phases of treatment
The different procedures performed by the machine [8]
include:
Prescription phase: this phase consists of decisions by
the prescribing clinician about the required modality
and related operational parameters and includes
periodic reassessment and/or change of the prescription.
Preparation phase: this phase consists of collection of
necessary disposable material, identification and
checking of the disposable set, set loading (cassette
tubing), connection to the filter, positioning of the
tubing, and hanging of bags.
Priming phase: priming solution is infused into the
extracorporeal circuit in order to remove air and
impurities remaining after sterilization of the set. When
heparin anticoagulation is used, it is usually added to
the priming solution. During this phase, the machine
makes a general check of all components and sensors.
Connection to the patient: this phase consists of the
connection of the extracorporeal lines to the patient’s
vascular access.
Treatment phase: net ultrafiltration and diffusive and/or
convective solute transport are activated (all the pumps
are working) and blood purification is performed. The
patient’s vital signs and circuit pressures must be
monitored throughout the treatment phase.
Special procedures: during treatment, special
procedures can include replenishment of dialysate,
replacement fluid, and citrate bags (when citrate
anticoagulation is used), change of syringes (when
using heparin anticoagulation), repositioning of the
vascular access, and temporary disconnection,
recirculation, and replacement of filter and kit.
Blood return, disconnection and unload: the blood
return procedure returns the blood to the patient.
This is usually done by connecting a saline solution bag
to the in-flow blood line and running the blood pump.
When the circuit is flushed, the blood pump is stopped,
the blood outflow line disconnected, and the tubing
and filter unloaded.
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CRRT disposables
Disposables (single-use components of the extracorpor-
eal circuit) are specific for every machine and are usually
designed for a specific treatment modality. The main
disposables [9] and color codes that should mark each
tubing line are listed in Table 1.
During CRRT, the filter is the key disposable through
which blood or plasma is effectively purified by ultrafiltra-
tion, convection, and/or diffusion. Historically, the desig-
nation “filter” describes the entire purifying extracorporeal
device system (i.e., membranes, housing, etc.). Among the
different types of filters, hemofilters, hemodialyzers, and
hemodiafilters should be used when exclusively convect-
ive, diffusive, or convective plus diffusive modalities, re-
spectively, are applied. In this article we use these terms
distinctly, taking into account the different CRRT modal-
ities. A plasma filter is defined as a specific filter that
allows the separation of plasma from cellular elements.
Sorbents, cartridges, and adsorbers do not belong to
the category of filters; in this case, adsorption is the
only purifying modality. The only available type of
CRRT filter that can perform diffusive and/or convective
transport is shaped as a collection of parallel “hollow
fibers”. The filters can be mainly identified by membrane
geometrics and performance characteristics [10–12].
Volume management and fluid balance
Fluid management during CRRT must take into account
the volume and hemodynamic status of the patient. The
machine fluid balance error is the fluid management error
caused by CRRT machine malfunction. Based on the in-
herent variability (“tolerances”) in the performance of the
fluid pumps, scales, and other components of a CRRT
machine’s fluid management system, the manufacturer
provides a specified limit (“specification”) beyond which a
fluid imbalance is considered an error. Fluid imbalances
can be due to hardware (scales, pumps, tubes) or software
(control system and protective subsystem) errors. Vari-
ous systems have been proposed for fluid balancing in
CRRT machines:
– Gravimetric fluid balancing, using one or more scales,
is most commonly used in CRRT because it is the
most reliable technique during long treatment
intervals. A fundamental aspect of this type of system
is the continuous weighing of the effluent along with
replacement fluid and/or dialysate, with weight acting
as a surrogate for fluid flow rate. The machine
software analyzes these scale data on an ongoing basis
and any discrepancies between prescribed and actual
values lead to adjustments in pump rates based on a
servo-feedback mechanism. Disadvantages include
limitations in scale capacity, user errors, and other
disturbances of the operating environment.
– In volumetric fluid balancing, a system of balancing
chambers and valves is used. During long treatments,
volumetric balancing is less accurate than gravimetric
balancing because of systematic, cumulative errors,
as there is no continuous servo-feedback safeguard
for this approach. The advantage of this system is
that it eliminates the need to collect effluent and thus
reduces the frequency of fluid-related interventions.
– Fluxometric fluid balancing requires the application
of accurate but expensive flow meters (electromagnetic,
ultrasonic and Coriolis flow meters).
All these methods can be applied individually or in
combination.
Extracorporeal therapies and treatments
Extracorporeal therapies can be categorized according to
session frequency and duration.
Continuous therapies
CRRT is any extracorporeal technique that replaces kid-
ney function and more generally provides blood purifica-
tion for an extended period of time. CRRT is considered
by many clinicians to be the most appropriate modality
for the management of hemodynamically unstable patients
with AKI, promoting better hemodynamic stability, reduced
transcellular solute shifts, and better tolerance to fluid re-
moval than intermittent extracorporeal therapies. The need
for expertise, the necessity of continuous anticoagulation,
the nursing workload, the continuous alarm vigilance, and
the higher costs are some of the limitations of this ap-
proach. CRRT can be provided in various forms depending
on resources, patient needs, and staff skills [5, 13, 14]
(Fig. 2).
Prescription should be reviewed regularly.
CRRT treatments are currently performed using a double
lumen catheter as vascular access, a “veno-venous” tech-
nique whereby blood is driven from a vein and, after be-
ing purified, returned to the same vein. “Arterio-venous”
circuits have been virtually abandoned.
Slow continuous ultrafiltration
Slow continuous ultrafiltration (SCUF), based only on
slow removal of plasma water, is used for patients with
refractory fluid overload, with or without renal dysfunction.
Its primary aim is to achieve safe and effective correction of
fluid overload.
Continuous veno-venous hemofiltration
Continuous veno-venous hemofiltration (CVVH) uses con-
vection, with ultrafiltrate replaced in part or completely
with appropriate replacement fluids, to achieve solute
clearance and volume control. Replacement fluid can
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Table 1 Main disposables and their components with associated color code in a CRRT extracorporeal circuit (modified from [45])
Tubes
Blood in-flow line (red; previously
known as access or arterial line)
Segment connecting the patient’s vascular access to the filter
Segment for pressure measurement (upstream blood pump): segment of the blood in-flow line
connected to the in-flow pressure sensor
Pump segment line: segment inserted between the rotor and the stator of the blood pump
Blood in-flow air removal chamber: allows removal of light air bubbles before the blood enters the
filter
Segment for pressure measurement (downstream blood pump): segment of the blood in-flow line
connected to the pre-filter pressure sensor
Blood out-flow line (dark blue;
previously known as return or venous line)
Segment connecting the filter to the patient’s vascular access
Segment for pressure measurement: segment of the blood out-flow line connected to the out-flow
pressure sensor
Blood out-flow air removal chamber: allows removal of light air bubbles before the blood returns to
the patient
Effluent/ultrafiltrate line (yellow) Segment that allows the flow of waste fluids from the filter
Pump segment line: segment inserted between the rotor and the stator of the effluent/ultrafiltrate
pump
Segment for pressure measurement: segment of the effluent line connected to the effluent/ultrafiltrate
pressure sensor
Dialysate line (green) Segment that allows the flow of incoming dialysate into the filter
Pump segment line: segment inserted between the rotor and the stator of the dialysate pump
Segment for pressure measurement (if present): segment of the dialysate line connected to the
dialysate pressure sensor
Heater line: segment of the dialysate line placed in contact with the heater
Replacement line (purple or light blue) Segment that allows the flow of replacement fluid into the blood in-flow and/or blood out-flow lines
Pump segment line: segment inserted between the rotor and the stator of the replacement pump
Segment for pressure measurement (if present): segment of the replacement line connected to the
replacement pressure sensor
Heater line: segment of the replacement line placed in contact with the heater
Pre-blood line (orange) Segment that allows the flow of specific fluids (mainly regional anticoagulants) into the blood in-flow
line before the blood pump
Pump segment line: segment inserted between the rotor and the stator of the pre-blood pump
Segment for pressure measurement (if present): segment of the pre-blood line connected to the
pre-blood pressure sensor
Anticoagulant and specific antagonists
line
Segments connecting the anticoagulant/specific antagonist bag or pump to the main blood circuit
Citrate line (orange): segment for citrate infusion (i.e., pre-blood line)
Heparin line (white): segment connecting the heparin syringe pump to the blood in-flow line
Specific antagonist line (black): segment connecting the specific antagonist syringe pump to
the blood out-flow line
Filter
Fiber (membranes) Every fiber, hollow and of cylindrical shape, allows the transport of fluids and solutes through their
porous semi-permeable surface
Bundle Entire number of fibers inside the housing
Housing Plastic casing containing a single membrane fiber bundle
Blood in-flow port: entrance port of blood entering into the filter
Blood out-flow port: exit port of blood leaving the filter
Dialysate in-flow port: entrance port of fresh dialysate
Effluent/ultrafiltrate out-flow port: exit port of waste solution
Potting Polyurethane component fixing the bundle within the housing and embedding the bundle at both
ends of the filter
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be infused before (predilution) and/or after (postdilution)
the hemofilter.
Continuous veno-venous hemodialysis
Continuous veno-venous hemodialysis (CVVHD) is a form
of continuous hemodialysis characterized by counter-
current/co-current dialysate flow rate into the dialysate
compartment of the hemodialyzer. The main mechanism
of transmembrane solute transport is diffusion.
Continuous veno-venous hemodiafiltration
Continuous veno-venous hemodiafiltration (CVVHDF)
combines hemodialysis and hemofiltration modalities.
Ultrafiltrate is replaced in part or completely by replace-
ment fluid (pre- or post-infusion) and counter-current/
co-current dialysate flow into the dialysate compartment.
Solute clearance is achieved via diffusive and convective
clearance.
Continuous veno-venous high-flux hemodialysis
Continuous veno-venous high-flux hemodialysis (CVVHFD)
consists of the same treatment as in CVVHD but carried
out using high-flux membranes. Due to the high-flux
properties of the membrane, a convective component of
solute clearance is achieved even if replacement fluid is
not infused.
Intermittent therapies
Intermittent therapies are carried out in sessions of 3–5 h.
They require adequate vascular access, specially trained
nurses, and water processing and sterilization that pro-
duces pure water for dialysate. Since treatment times are
relatively short, the depuration rate must be higher than
that of CRRT. The most commonly prescribed inter-
mittent therapies are intermittent hemodialysis (IHD),
intermittent hemofiltration (IHF), intermittent hemo-
diafiltration (IHDF), and intermittent high-flux dialysis
(IHFD). Other therapies are available combining different
Fig. 2 Main extracorporeal therapies and treatments (modified from [5]) Abbreviations: QB blood flow rate, QUF
NET net ultrafiltration flow rate,
QUF ultrafiltration flow rate, QD dialysate flow rate, QR total replacement flow rate, QEFF effluent flow rate, QP-R replacement plasma flow rate,
QP-UF plasma ultrafiltration flow rate, SCUF slow continuous ultrafiltration, CVVH continuous veno-venous hemofiltration, CVVHD continuous
veno-venous hemodialysis, CVVHDF continuous veno-venous hemodiafiltration, CVVHFD-SLED continuous veno-venous high-flux dialysis–sustained
low-efficiency dialysis, TPE therapeutic plasma exchange, HP hemoperfusion, CPFA continuous plasma filtration coupled with adsorption, HVHF
high-volume hemofiltration
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modalities but these are not usually performed in the
intensive care unit (ICU), so are not discussed here.
Hybrid therapies
With respect to frequency and duration, the term “hybrid
therapies” relates to the blending of characteristics from
both intermittent and continuous modalities. These ther-
apies attempt to optimize the advantages and minimize
the disadvantages of both modalities: efficient solute re-
moval, slower ultrafiltration rates for hemodynamic sta-
bility, less anticoagulant exposure, shorter duration,
lower costs, decreased nurse workload, and improved
ICU workflow. Hybrid therapies encompass various specific
“discontinuous” RRT modalities: sustained low-efficiency
dialysis (SLED), slow low-efficiency extended daily dialysis
(SLEDD), prolonged intermittent RRT (PIRRT), extended
daily dialysis (EDD), extended daily dialysis with filtration
(EDDf), extended dialysis (ED), “go slow dialysis”, and
accelerated veno-venous hemofiltration (AVVH).
Hybrid therapies are usually performed with standard
intermittent hemodialysis equipment, including machines,
filters, extracorporeal blood circuits, and, in some cases,
online fluid production for dialysate and ultrafiltrate
infusion. Solute removal is largely diffusive but variants
with a convective component, such as EDDf and AVVH,
are possible.
The most commonly prescribed hybrid therapy is SLED,
a technique that uses reduced blood and dialysate flow
rates and is usually limited to 8–12 h. Data from appropri-
ately powered studies on the application of these tech-
niques are limited [15].
Other extracorporeal therapies
Other blood purification techniques are also performed
in the ICU to clear toxins and solutes generally not re-
movable by “classic” RRT or to support single or multiple
organ dysfunction. While the delivery of CRRT may be
achieved without anticoagulation in some patients, these
therapies typically require some form of anticoagulation.
Therapeutic plasma exchange
Therapeutic plasma exchange (TPE) consists of the
automated removal of plasma (plasmapheresis) and its
replacement (exchange) with a suitable fluid composed
of fresh frozen plasma or albumin.
TPE is performed using a centrifugal-based system or
a very highly permeable membrane that allows separ-
ation of plasma from the cellular elements of blood. In
membrane-based TPE, pore sizes ranging between 0.2 and
0.6 microns allow a sieving coefficient of 0.9–1.0 for mole-
cules with a molecular weight greater than 500 kDa [16].
Continuous plasma exchange (CPE) is a therapy derived
from TPE that is performed with lower flow rates and for
a longer period of time. Single or repeated sessions can be
performed as pure CPE or in conjunction with other puri-
fication techniques.
Multiple organ support therapy
Recently, CRRT has been used in a wide range of “non-
renal applications”, including multiple organ support ther-
apies (MOSTs), to manage patients with multiple organ
dysfunction syndrome [17]. MOST requires a complex
extracorporeal support system with a multi-tasking ma-
chine platform and multiple devices. The type and inten-
sity of organ support therapy can be modulated according
to the number and severity of organ dysfunctions.
Heart support In myocardial dysfunction, right and left
ventricular dysfunction can be complicated by severe
fluid overload [18]. SCUF, performed in patients with or
without AKI, can reduce fluid overload, improve cardiac
filling volumes and contractility and is usually well toler-
ated among hemodynamically unstable cardiac failure
patients [19]. It may be especially worthy of consider-
ation in patients with severe diuretic resistance and car-
diorenal syndrome, for whom therapeutic options are
limited.
Liver support Artificial liver support includes “cell-based”
and “non-cell-based” devices, including conventional IHD,
CRRT, and devices specifically designed to clear accumu-
lated toxins associated with liver dysfunction [20, 21]
(Table 2). In many non-cell-based systems, an albumin-
enriched dialysate is necessary to remove such toxins
(e.g., fatty acids, hydrophobic bile acids, and nitric
oxide), which are highly albumin-bound. This “albumin
dialysis” concept forms the basis of single pass albumin
dialysis (SPAD) and the molecular adsorbent recirculat-
ing system (MARS) while Prometheus (Fresenius Medical
Care, Bad Homburg, Germany) is based on fractionated
plasma separation and adsorption (FPSA) [22].
Table 2 Liver support systems in the hepato-renal syndrome
(modified from [20])
Non-cell-based systems Intermittent, extended and continuous
dialysis techniques
Hemoperfusion techniques
Plasma exchange techniques
Plasmapheresis
Plasma filtration/adsorption
Albumin dialysis
• MARS
• SPAD
Prometheus
Cell-based systems (Bioartificial
liver support systems)
Human hepatocytes (bioartificial liver
support system)
Porcine hepatocytes
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1. Single pass albumin dialysis
In SPAD, albumin is used as a component of the
dialysate for more effective protein-bound toxin
removal. The blood is placed in contact with a
standard albumin-impermeable high-flux
membrane and is dialyzed against an albumin-
containing dialysate. Protein-bound molecules
that are small enough to pass from the blood
compartment through the membrane pores are
dialyzed and then bound to albumin in the
dialysate. SPAD provides a single pass of fresh
albumin dialysate; this characteristic constitutes
the major difference between SPAD and MARS
[23, 24].
2. Molecular adsorbent recirculating system
MARS uses a hemodialyzer in a primary circuit,
which is connected to a secondary circuit composed
of a standard hemodialyzer, an activated carbon
adsorber and an anion exchanger. In the primary
circuit, the patient’s blood is pumped into the
MARS hemodialyzer and water-soluble substances
diffuse through the dialysate solution. This mem-
brane has a size selection threshold of less
than 60 kDa, thus retaining albumin on the blood
side; only the free fraction of toxins can cross the
membrane in a manner similar to SPAD. The dialys-
ate compartment of the MARS hemodialyzer
is part of a secondary circuit, where a 20 % albumin
solution circulates in a counter-current flow. Toxins
can bind to the free albumin in the secondary cir-
cuit, while clearance of water-soluble substances oc-
curs in a standard CRRT hemodialyzer.
Hydrophobic albumin-bound toxins are then extra-
ctedby passage through activated charcoal and anion
exchange columns, thus regenerating the albumin
binding sites. The reconstituted albumin is then
recirculated to maintain a transmembrane concen-
tration gradient in the primary circuit hemodialyzer.
3. Prometheus FPSA
The Prometheus system is based on FPSA
combined with hemodialysis. The patient’s blood
is pumped toward a specific albumin-permeable
membrane with a size-selection threshold of
250 kDa. The albumin fraction of blood is
selectively filtered and albumin-bound toxins
can freely pass the membrane by convection. In a
secondary circuit, the filtered albumin-rich plasma
fraction is treated by two absorber columns: a
neutral resin absorber and an anion exchanger
for removal of negatively charged toxins. The
purified albumin-rich plasma fraction is re-infused
into the primary circuit where, in a second
step, conventional hemodialysis is performed to
eliminate water soluble molecules [25, 26].
Lung support There is well-established evidence of inter-
action between lung and kidney functions and many crit-
ically ill patients may require concomitant extracorporeal
kidney and lung support [27, 28]. In most cases, CRRT
can be performed with the same vascular access used for
extracorporeal lung support therapies, both for therapies
requiring high blood flows (extracorporeal membrane
oxygenation (ECMO) [29]) and, more recently, for therap-
ies requiring low blood flows. ECMO is frequently per-
formed in conjunction with CRRT and different circuit
configurations can be used [27]. Conventional ECMO
systems typically require blood flow rates substantially
higher than those used in CRRT, although new therapies
using lower blood flows may even be sufficient to achieve
adequate extracorporeal oxygenation [30]. On the other
hand, new lung support modalities utilizing blood flow
rates similar to those applied in CRRT (and capable of be-
ing provided by CRRT machines) are sufficient to perform
extracorporeal CO2 removal [31].
Blood purification in sepsis In patients with hyper-
inflammation (mainly during sepsis), extracorporeal blood
purification therapies have the potential to modulate the
host inflammatory response through the removal of in-
flammatory mediators and/or bacterial toxins.
1. High-volume hemofiltration
Although not unequivocally defined in the medical
literature, high-volume hemofiltration (HVHF; Fig. 2)
is identified as continuous treatment with a convective
target dose (prescribed) greater than 35 ml/kg/h
[32, 33]. Continuous treatments with a dose
greater than 45 ml/kg/h identify very high-volume
hemofiltration (VHVHF) modalities. Intermittent
procedures with brief, very high-volume treatments at
100 to 120 ml/kg/h for 4–8 h, followed by conventional
CVVH, are identified as pulse HVHF [34].
However, there is no evidence that HVHF, when
compared with standard dose hemofiltration, leads
to a reduction in mortality [35]. There is insufficient
evidence to routinely recommend the use of HVHF
in critically ill patients with severe sepsis and/or
septic shock except as interventions being investigated
in the setting of a randomized clinical trial.
2. Continuous plasmafiltration coupled with adsorption
Continuous plasmafiltration coupled with adsorption
(CPFA) is a blood purification therapy (Fig. 2) that
combines the advantages of CRRT and continuous
plasma filtration without requiring large amounts
of plasma substitutes. In the first step of CPFA,
a plasma filter separates plasma from the blood
cellular component and the plasma filtrate is
pumped through a sorbent. The purified plasma is
then returned to the main circuit where blood is
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reconstituted and treated with standard CRRT
modalities. There is no evidence that CPFA reduces
mortality in patients with septic shock or that it
positively affects other important clinical
outcomes [36].
3. Hemoperfusion
Continuous hemoperfusion involves placement of a
sorbent cartridge in series with the filter (Fig. 2) in
order to remove those toxins that are not removable
by classic CRRT. The sorbent is placed in direct
contact with blood and adsorbs solutes through
hydrophobic interactions, ionic attraction, hydrogen
bonds, and van der Waals interactions [37].
Hemoperfusion requires an extremely biocompatible
sorbent coated with a surface that prevents platelet
adhesion and clotting activation. The removal
characteristics of hemoperfusion are dependent on
the different types of sorbent used, with effective
surface area playing an important role.
Polymyxin (PMX)-hemoperfusion is a technique
based on the use of a cartridge containing fibers
coated with PMX B, an antibiotic with high affinity
for lipopolysaccharide. The aim is to remove
circulating endotoxin. Results from studies of
PMX-hemoperfusion have been controversial.
Nevertheless, the most recent results seem to
suggest no improvement in organ failure in patients
treated with PMX-hemoperfusion [38, 39].
Conclusions
Application of technology at the bedside requires full
knowledge of the basic principles and the operating
mechanisms for every technique. When faced with a
complex patient, practitioners can use a growing variety
of extracorporeal treatment options. For patients with
multiple organ failure, an increasingly rich panoply of
options is being developed, including extracorporeal treat-
ments for sepsis and for cardiac, pulmonary, and liver fail-
ure [40–44]. In this complex scenario, a multidisciplinary
clinical care team composed of specialists from different
disciplines and highly trained nurses is crucial to the
success of the treatment. We suggest a framework for
harmonization of terminology to reduce the errors and
complications that can result from poor understanding
and inadequate delivery of the prescribed therapies. Ho-
mogenized nomenclature is also important when report-
ing machine functions and clinical parameters to enable
study comparisons and advance our understanding in this
field, ultimately allowing for improvements in clinical
practice and patient outcomes.
We trust that new publications, electronic medical re-
cords, and machine software will be designed and operated
in compliance with the agreed terminology to enable con-
sistent data collection and comparison.
Acknowledgements
Members of the Nomenclature Standardization Initiative Alliance and Signing
Members of the Charta of Vicenza:
Bagshaw SM, Critical Care Medicine, University of Alberta, Edmonton, Canada
Balducci A, Estor Spa, Pero (MI), Italy
Baldwin I, Austin Health, Heidelberg, Australia
Barbarigo F, Ospedale S. Bortolo, Vicenza, Italy
Bellomo R, The University of Melbourne, Melbourne, Australia
Braganò P, Estor Spa, Pero (MI), Italy
Braunsky J, NxStage Medical Inc., Lawrence, MA, USA
Calletti F, SINED srl, Cadriano di Granarolo, Bologna, Italy
Cerda J, Albany Medical College, Albany, NY, USA
Chawla L, George Washington University, Washington, DC, USA
De Rosa S, St. Bortolo Hospital and IRRIV, Vicenza, Italy
Di Somma S, Università La Sapienza e Ospedale Sant’Andrea, Roma, Italy
Doi K, Critical Care Medicine, The University of Tokyo, Tokyo, Japan
Dosil Rosende P, Asahi Kasei Medical GmbH, Frankfurt, Germany
Emmett M, Baylor University Medical Center, Dallas, TX, USA
Fecondini L, Medica SpA, Medolla (MO), Italy
Galavotti D, Rand Srl, Medolla (MO), Italy
Garzotto F, IRRIV, St Bortolo Hospital, Vicenza, Italy
Gibney N, University of Alberta, Edmonton, Canada
Goldstein SL, Cincinnati Children’s Hospital, Cincinnati, OH, USA
Guadagni G, Spectral Medical Inc., Toronto, Ontario, Canada
Honoré P, ICU, UZ Brussel, VUB University, Brussels, Begium
Hoste E, Ghent University Hospital, Gent, Belgium
Inadome S, Asahi Kasei Medical GmbH, Frankfurt, Germany
Kashani K, Mayo Clinic, Rochester, MN, USA
Katz N, Johns Hopkins University, Baltimore, MD, USA
Kellum J, Center for Critical Care Nephrology, Dept of Critical Care Medicine,
University of Pittsburgh, Pittsburgh, USA
Kenley R, Aethlon Medical Inc., Libertyville, IL, USA
Kobayashi Y, Asahi Kasei Medical GmbH, Frankfurt, Germany
Lannoy J, Nikkiso, Langenhagen, Germany
Lewington A, St. James’s University Hospital, Leeds, West Yorkshire, UK
Lorenzin A, IRRIV, St Bortolo Hospital, Vicenza, Italy
Mariano F, Divisione Nefrologia Dialisi e Trapianto, Città della Salute e della
Scienza, Torino, Italy
McCullough PA, Baylor University Medical Center, Dallas, TX, USA
Mehta RL, University of California, San Diego, CA, USA
Menneguerre J, B. Braun Medical AG, Crissier, Switzerland
Mettifogo M, Dept Nephrology Dialysis &Transplantation, St Bortolo Hospital,
Vicenza, Italy
Neri M, IRRIV, St Bortolo Hospital, Vicenza, Italy
Ostermann M, Department of Critical Care & Nephrology, Guy’s & St. Thomas’
Hospital, London, UK
Pani A, Nefrologia e Dialisi, Ospedale G. Brotzu, Cagliari, Italy
Pirazzoli P, Bellco, Mirandola (MO), Italy
Pohlmeier R, Fresenius Medical Care, Bad Homburg v.d.H., Germany
Pouchoulin D, Gambro Industires, Meyzieu, France
Ricci Z, Ospedale Pediatrico Bambino Gesù, Roma, Italy
Ronco C, IRRIV, St Bortolo Hospital, Vicenza, Italy
Rosner M, University of Virginia, Charlottesville, VA, USA
Seamann M, Internal Medicine III, Medical University of Vienna, Viennna,
Austria
Shaw A, Vanderbilt University Medical Center, Nashville, TN, USA
Tolwani A, University of Alabama at Birmingham, Birmingham, AL, USA
Villa G, University of Florence, Firenze, Italy
Vincent J.L, Erasme Hospital, Université libre de Bruxelles, Brussels, Belgium
Wendon J, King’s College Hospital, London, UK
Funding
No sources of funding are declared for this manuscript.
Authors’ contributions
All authors attended the consensus expert conference, contributed to drafting,
reviewing, and editing the manuscript, and approved the final version.
Competing interests
The authors declare that they have no competing interests.
Villa et al. Critical Care  (2016) 20:283 Page 9 of 11
Author details
1Department of Nephrology, Dialysis and Transplantation, International Renal
Research Institute of Vicenza, San Bortolo Hospital, Viale Rodolfi 37, 36100
Vicenza, Italy. 2Department of Health Sciences, Section of Anaesthesiology,
Intensive Care and Pain, University of Florence, Florence, Italy. 3Department
of Management and Engineering, Universityof Padova, Vicenza, Italy.
4Department of Intensive Care, Austin Hospital, Department of Epidemiology
and Preventive Medicine, Australian and New Zealand Intensive Care
Research Centre, Monash University, Melbourne, Victoria, Australia.
5Department of Medicine, Albany Medical College, Albany, New York 12209,
USA. 6Intensive Care Department, Universitair Ziekenhuis Brussel, Vrije
Universiteit Brussel, Brussels, Belgium. 7Center for Critical Care Nephrology,
Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA,
USA. 8Service d’Anesthésie-Réanimation-SMUR, Lariboisière AP-HParis,
Université Paris Diderot-Paris, Paris, France. 9Department of Pediatric Cardiac
Surgery, Bambino Gesù Children’s Hospital, Rome, Italy. 10Institute of Life
Sciences, Sant’Anna School of Advances Studies, Pisa, Italy. 11Department of
Intensive Care, Erasme Hospital, Université libre de Bruxelles, Brussels,
Belgium. 12Liver Intensive Therapy Unit, Institute of Liver Studies, King’s
College London, Denmark Hill Campus, London, UK.
References
1. Ronco C. The Charta of Vicenza. Blood Purif. 2015;40(1):I–V.
2. Kellum JA, Bellomo R, Ronco C. Acute Dialysis Quality Initiative (ADQI):
methodology. Int J Artif Organs. 2008;31(2):90–3.
3. Ronco C, Bellomo R. Continuous renal replacement therapies: the need for
a standard nomenclature. Contrib Nephrol. 1995;116:28–33.
4. Ronco C, Bellomo R. Continuous renal replacement therapy:
evolution in technology and current nomenclature. Kidney Int
Suppl. 1998;66:S160–4.
5. Cerda J, Ronco C. Modalities of continuous renal replacement therapy:
technical and clinical considerations. Semin Dial. 2009;22(2):114–22.
6. Cruz D, Bobek I, Lentini P, Soni S, Chionh CY, Ronco C. Machines for
continuous renal replacement therapy. Semin Dial. 2009;22(2):123–32.
7. Ward RA, Ronco C. Dialyzer and machine technologies: application of recent
advances to clinical practice. Blood Purif. 2006;24(1):6–10.
8. Baldwin I, Fealy N. Clinical nursing for the application of continuous
renal replacement therapy in the intensive care unit. Semin Dial.
2009;22(2):189–93.
9. Misra M. The basics of hemodialysis equipment. Hemodial Int. 2005;9(1):30–6.
10. Clark WR, Gao D, Ronco C. Membranes for dialysis. Composition, structure
and function. Contrib Nephrol. 2002;137:70–7.
11. Uhlenbusch-Korwer I, Bonnie-Schorn E, Grassman A, Vienken J. Performance
parameters. In: Understanding Membranes and Dialyzers. Edited by Vienken
J, vol. 5: Pabst; 2004. p. 103–155.
12. Winchester JF. Sorbent hemoperfusion in end-stage renal disease: an
in-depth review. Adv Ren Replace Ther. 2002;9(1):19–25.
13. Bellomo RRC, Mehta RA. Nomenclature for continuous renal replacement
therapies. Am J Kidney Dis. 1996;28(5 S3):S2–7.
14. Cerda J, Sheinfeld G, Ronco C. Fluid overload in critically ill patients with
acute kidney injury. Blood Purif. 2010;29:11–8.
15. Schwenger V, Weigand MA, Hoffmann O, Dikow R, Kihm LP, Seckinger J,
Miftari N, Schaier M, Hofer S, Haar C, et al. Sustained low efficiency dialysis
using a single-pass batch system in acute kidney injury–a randomized
interventional trial: the REnal Replacement Therapy Study in Intensive Care
Unit PatiEnts. Crit Care. 2012;16(4):R140.
16. Kaplan AA. Therapeutic plasma exchange: a technical and operational
review. J Clin Apher. 2013;28(1):3–10.
17. Brendolan A, Bellomo R, Ronco C. Multiple-Organ Support Therapy for the
Critically Ill Patient. In: Critical Care Nephrology. Ronco C, Bellomo R, Kellum
J, editors. 2nd edn. Saunders Elsevier; 2009. p. 1571–1577.
18. Mathew RO, Cerda J. Renal replacement therapy in special situations: heart
failure and neurological injury. Semin Dial. 2011;24(2):192–6.
19. Wei SS, Lee WT, Woo KT. Slow continuous ultrafiltration (SCUF)–the safe and
efficient treatment for patients with cardiac failure and fluid overload.
Singapore Med J. 1995;36(3):276–7.
20. Cerda J, Tolwani A, Gibney N, Tiranathanagul K. Renal replacement therapy
in special settings: extracorporeal support devices in liver failure. Semin Dial.
2011;24(2):197–202.
21. Stadlbauer V, Wright GA, Jalan R. Role of artificial liver support in hepatic
encephalopathy. Metab Brain Dis. 2009;24(1):15–26.
22. Rademacher S, Oppert M, Jorres A. Artificial extracorporeal liver support
therapy in patients with severe liver failure. Expert Rev Gastroenterol
Hepatol. 2011;5(5):591–9.
23. Peszynski P, Klammt S, Peters E, Mitzner S, Stange J, Schmidt R. Albumin
dialysis: single pass vs. recirculation (MARS). Liver. 2002;22 Suppl 2:40–2.
24. Mitzner S, Klammt S, Stange J, Schmidt R. Albumin regeneration in liver
support-comparison of different methods. Ther Apher Dial. 2006;10(2):108–17.
25. Falkenhagen D, Strobl W, Vogt G, Schrefl A, Linsberger I, Gerner FJ,
Schoenhofen M. Fractionated plasma separation and adsorption system: a
novel system for blood purification to remove albumin bound substances.
Artif Organs. 1999;23(1):81–6.
26. Rifai K, Ernst T, Kretschmer U, Hafer C, Haller H, Manns MP, Fliser D. The
Prometheus device for extracorporeal support of combined liver and renal
failure. Blood Purif. 2005;23(4):298–302.
27. Askenazi DJ, Selewski DT, Paden ML, Cooper DS, Bridges BC, Zappitelli M,
Fleming GM. Renal replacement therapy in critically ill patients
receiving extracorporeal membrane oxygenation. Clin J Am Soc
Nephrol. 2012;7(8):1328–36.
28. Fleming GM, Askenazi DJ, Bridges BC, Cooper DS, Paden ML, Selewski DT,
Zappitelli M. A multicenter international survey of renal supportive therapy
during ECMO: the Kidney Intervention During Extracorporeal Membrane
Oxygenation (KIDMO) group. ASAIO J. 2012;58(4):407–14.
29. Mosier JM, Kelsey M, Raz Y, Gunnerson KJ, Meyer R, Hypes CD, Malo J,
Whitmore SP, Spaite DW. Extracorporeal membrane oxygenation (ECMO) for
critically ill adults in the emergency department: history, current
applications, and future directions. Crit Care. 2015;19:431.
30. Walles T. Clinical experience with the iLA Membrane Ventilator
pumpless extracorporeal lung-assist device. Expert Rev Med Devices.
2007;4(3):297–305.
31. Cove ME, MacLaren G, Federspiel WJ, Kellum JA. Bench to bedside review:
Extracorporeal carbon dioxide removal, past present and future. Crit Care.
2012;16(5):232.
32. Kellum JA, Mehta RL, Angus DC, Palevsky P, Ronco C. The first international
consensus conference on continuous renal replacement therapy. Kidney Int.
2002;62(5):1855–63.
33. Clark E, Molnar AO, Joannes-Boyau O, Honore PM, Sikora L, Bagshaw SM.
High-volume hemofiltration for septic acute kidney injury: a systematic
review and meta-analysis. Crit Care. 2014;18(1):R7.
34. Brendolan A, D’Intini V, Ricci Z, Bonello M, Ratanarat R, Salvatori G, Bordoni V,
De Cal M, Andrikos E, Ronco C. Pulse high volume hemofiltration. Int J Artif
Organs. 2004;27(5):398–403.
35. Joannes-Boyau O, Honore PM, Perez P, Bagshaw SM, Grand H, Canivet JL,
Dewitte A, Flamens C, Pujol W, Grandoulier AS, et al. High-volume versus
standard-volume haemofiltration for septic shock patients with acute kidney
injury (IVOIRE study): a multicentre randomized controlled trial. Intensive
Care Med. 2013;39(9):1535–46.
36. Livigni S, Bertolini G, Rossi C, Ferrari F, Giardino M, Pozzato M, Remuzzi G.
Efficacy of coupled plasma filtration adsorption (CPFA) in patients with
septic shock: a multicenter randomised controlled clinical trial. BMJ Open.
2014;4(1):e003536.
37. Winchester JF, Kellum JA, Ronco C, Brady JA, Quartararo PJ, Salsberg JA,
Levin NW. Sorbents in acute renal failure and the systemic inflammatory
response syndrome. Blood Purif. 2003;21(1):79–84.
38. Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, Pottecher J,
Joannes-Boyau O, Martin-Lefevre L, Jabaudon M, et al. Early use of polymyxin B
hemoperfusion in patients with septic shock due to peritonitis: a multicenter
randomized control trial. Intensive Care Med. 2015;41(6):975–84.
39. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V,
Petrini F, Volta G, Bobbio Pallavicini FM, et al. Early use of polymyxin B
hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled
trial. JAMA. 2009;301(23):2445–52.
40. Palevsky PM. Dialysis modality and dosing strategy in acute renal failure.
Semin Dial. 2006;19(2):165–70.
41. Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury D,
Finkel K, Kellum JA, Paganini E, Schein RM, et al. Intensity of renal
support in critically ill patients with acute kidney injury. N Engl J Med.
2008;359(1):7–20.
42. Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, McArthur C,
McGuinness S, Myburgh J, Norton R, et al. Intensity of continuous
Villa et al. Critical Care  (2016) 20:283 Page 10 of 11
renal-replacement therapy in critically ill patients. N Engl J Med.
2009;361(17):1627–38.
43. Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I,
Bouman C, Macedo E, Gibney N, et al. Timing of renal replacement therapy
and clinical outcomes in critically ill patients with severe acute kidney injury.
J Crit Care. 2009;24(1):129–40.
44. Macedo E, Mehta RL. When should renal replacement therapy be initiated
for acute kidney injury? Semin Dial. 2011;24(2):132–7.
45. Neri M, Cerdà J, Garzotto F, Villa G, Ronco C. Nomenclature for Renal
Replacement Therapy in Acute Kidney Injury. In: Continuous Renal
Replacement Therapy. Kellum J, Bellomo R, Ronco C, editors. 2nd edn.
Oxford University Press; 2016. p. 21–34.
Villa et al. Critical Care  (2016) 20:283 Page 11 of 11
